Dr. Warren Sherman is a renowned interventional cardiologist with a long and established focus in cell-based therapies. As Chief Medical Officer and a treating physician at Okyanos, Dr. Sherman provides the highest level of care using stem cell therapies for patients with chronic heart failure and refractory angina. He is board certified in cardiovascular disease and interventional cardiology with the American Board of Internal Medicine.
Recently, Dr. Sherman served as Chief Medical Officer, first at Celyad, SA and then at LoneStar Heart, Inc, both leading biotech companies specializing in the discovery and development of regenerative, protective and reconstructive therapies.
Over the last decade, Dr. Sherman held a number of prominent positions at Columbia University Medical Center in New York, including Director of Stem Cell Research and Regenerative Medicine at the Center for Interventional Vascular Therapy, and Associate Professor of Medicine. He maintained an active role in the Center’s training and clinical care programs and received teaching awards as well as wide recognition for patient care both as an interventional and general cardiologist. During that time, Dr. Sherman founded the Cardiovascular Research Foundation’s annual International Conference on Cell Therapy for Cardiovascular Disease (IC3D). IC3D became the standard bearer for scientific exchange and program development for the burgeoning field of cardiovascular repair and regeneration, by fostering collaboration through its extensive network of scientists, sponsors, regulators and investors.
Dr. Sherman moved to Mount Sinai Hospital in New York in 1983 to investigate new techniques for treating patients with acute myocardial infarction. He served as Director of Medical Education and Associate Director, Cardiac Catheterization Laboratories of the Zena and Michael A. Wiener Cardiovascular Institute of Mount Sinai Hospital New York, New York. In 1989, he shifted to a fully clinical role and created the Interventional Cardiology Program at Beth Israel Medical Center in New York City.
With a deepening interest in myocardial regenerative techniques, Dr. Sherman pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of adult stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. This technique was then brought to the U.S., where he performed a similar procedure at Mount Sinai Hospital in April 2003. As Director of Cell Therapy at Mount Sinai Hospital, Dr. Sherman was the principal investigator of a multicenter clinical study of autologous skeletal myoblast injections for patients with congestive heart failure and the lead investigator on numerous translational studies.
Dr. Sherman received his Bachelor of Science from the Massachusetts Institute of Technology, Doctorate in Medicine from the State University of New York Upstate Medical School in Syracuse and Fellowship in Cardiovascular Diseases from Oregon Health Sciences University, in Portland, Oregon.
A proven leader in advancing novel treatments for cardiac disease throughout his highly successful career, Dr. Sherman serves as scientific and clinical advisor to a multitude of government organizations, societies and industries. He has authored or co-authored numerous publications in the emerging field of myocardial regeneration.